Quizartinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 375 publications

Design, Synthesis, and Evaluation of Benzimidazole-Based HDAC Inhibitors: Synergistic Effect with FLT3 Inhibitor against AML via Modulation of Tumor Metabolism.

Design, Synthesis, and Evaluation of Benzimidazole-Based HDAC Inhibitors: Synergistic Effect with FLT3 Inhibitor against AML via Modulation of Tumor Metabolism.

Journal: Journal of medicinal chemistry
Published: June 18, 2026

Quizartinib: FLT3-ITD or not, does it matter?

Quizartinib: FLT3-ITD or not, does it matter?

Journal: Haematologica
Published: June 05, 2026

Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.

Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.

Journal: Leukemia & lymphoma
Published: May 30, 2026

Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia.

Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia.

Journal: Journal of medicinal chemistry
Published: May 23, 2026

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.

Journal: Folia biologica
Published: April 14, 2026

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Journal: Haematologica
Published: April 01, 2026

Reply to: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.

Reply to: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026

Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis.

Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis.

Journal: Frontiers in oncology
Published: March 16, 2026

Statistical Inference of Phenotype-Specific Molecular Mechanisms from Cell Line-Specific Gene Regulatory Networks with Application to Quizartinib Sensitivity.

Statistical Inference of Phenotype-Specific Molecular Mechanisms from Cell Line-Specific Gene Regulatory Networks with Application to Quizartinib Sensitivity.

Journal: International journal of molecular sciences
Published: March 15, 2026

Myopericarditis After Combined Idarubicin and Quizartinib in FLT3-ITD-Positive AML.

Myopericarditis After Combined Idarubicin and Quizartinib in FLT3-ITD-Positive AML.

Journal: JACC. Case reports
Published: March 11, 2026

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica
Published: March 10, 2026
Showing 1-12 of 375

Last Updated: 06/30/2026